A recent research letter in JAMA looked at crowd-diagnoses via social media to determine whether they were for a second opinion after seeing a health care professional.
©Samuel Borges Photography - shutterstock.com
Social media is ubiquitous today, but one area that has not been fully investigated is its effect on medical diagnoses. A recent research letter in JAMA looked at crowd-diagnoses via social media to determine whether they were for a second opinion after seeing a health care professional.
Methods
The authors focused their study on Reddit, a social media website with 330 million monthly active users that hosts more than 232 health forums. The research focused exclusively on the subreddit, (r/STD), which allows users to publicly share “stories, concerns, and questions” about “anything and everything STD [sexually transmitted disease]-related.”
The authors obtained all posts from the inception of the subreddit in November 2010 through February 2019. They then drew a random sample of 500 posts and independently coded whether each post requested a crowd-diagnosis, and if so, whether that request was made to obtain a second opinion after seeing a healthcare professional.
Findings
The r/STD subreddit included 16,979 total posts. There was an 80% agreement among all coders on crowd-diagnoses (Cohen κ = 0.73) and 88% agreement on whether the crowd-diagnoses were requests for a second opinion (Cohen κ = 0.53) among an overlapping sample of 50 posts.
The authors found that:
Conclusions
The authors admit that there are a few limitations to this study. It was limited to one social media platform and a single medical condition. Perhaps more importantly, the accuracy of the diagnoses and whether individuals acted on the provided advice were not investigated.
The authors suggest that health care professionals could “partner with social media outlets to promote the potential benefits of crowd-diagnosis while suppressing potential harms, for example by having trained professionals respond to posts to better diagnose and make referrals to health care centers.”
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
Understanding VTE and bleeding risks in gynecologic noncancer surgery
April 15th 2024Delve into the nuanced risks of venous thromboembolism and major bleeding post-gynecologic noncancer surgery, exploring procedure-specific variations and the implications for thromboprophylaxis strategies.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Trends in STI prevalence and testing guidelines
April 11th 2024In a recent interview, Cheruba Prabakar, MD, FACOG, shed light on the rising prevalence of sexually transmitted infections in the United States and the need for improved awareness and testing, particularly for overlooked conditions such as trichomoniasis.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
Understanding VTE and bleeding risks in gynecologic noncancer surgery
April 15th 2024Delve into the nuanced risks of venous thromboembolism and major bleeding post-gynecologic noncancer surgery, exploring procedure-specific variations and the implications for thromboprophylaxis strategies.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Trends in STI prevalence and testing guidelines
April 11th 2024In a recent interview, Cheruba Prabakar, MD, FACOG, shed light on the rising prevalence of sexually transmitted infections in the United States and the need for improved awareness and testing, particularly for overlooked conditions such as trichomoniasis.
Read More
2 Commerce Drive
Cranbury, NJ 08512